{"gene":"CEBPD","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1992,"finding":"CEBPD (NF-IL6β) forms a heterodimer with NF-IL6 (C/EBPβ) in vitro, and the heterodimeric complex binds the same DNA sequences as respective homodimers; CEBPD shows synergistic transcriptional activation with NF-IL6 in transient luciferase assays.","method":"In vitro heterodimerization assay, EMSA, transient luciferase reporter assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of heterodimerization combined with DNA-binding and transactivation assays","pmids":["1741402"],"is_preprint":false},{"year":1993,"finding":"CEBPD is the major IL-1-inducible protein that binds the C/EBP site in the C3 promoter and trans-activates the human complement C3 gene in an IL-1-responsive manner; CEBPD protein accumulates in the nucleus after IL-1 treatment of Hep3B cells.","method":"EMSA with supershift antibodies, Western immunoblot, co-transfection reporter assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — supershift EMSA, Western blot, and functional reporter assay in a single study with rigorous controls","pmids":["8385337"],"is_preprint":false},{"year":1993,"finding":"CEBPD (C/EBPδ/NF-IL6β) is transcriptionally induced by IL-6 in Hep3B hepatoma cells and constitutively activates transcription from IL-6 responsive elements (IL-6REs) in the promoters of hemopexin, haptoglobin, and CRP, unlike IL-6DBP/NF-IL6 whose activity is regulated post-translationally.","method":"Transient transfection reporter assay, Western blot of nuclear extracts","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods, distinguishes transcriptional vs post-translational regulation mechanisms","pmids":["7680115"],"is_preprint":false},{"year":1993,"finding":"The human CEBPD gene is intronless and maps to the pericentromeric region of chromosome 8 (8q11), with its protein product binding CCAAT homology and viral enhancer core sequences.","method":"cDNA/genomic cloning, FISH, somatic cell hybrid mapping","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct chromosomal localization by FISH with STS confirmation","pmids":["8314590"],"is_preprint":false},{"year":1995,"finding":"CEBPD (NF-IL6β) physically interacts with PU.1 through its leucine zipper domain and the carboxyl-terminal 28 amino acids of PU.1 (Ets domain); the two proteins synergistically activate transcription and can simultaneously bind adjacent DNA sites without altering each other's DNA-binding kinetics.","method":"Far Western blot, cDNA library screen, EMSA, transient transfection synergy assay, deletion mutagenesis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — Far Western library screen plus EMSA plus functional synergy assay with deletion mapping","pmids":["7594592"],"is_preprint":false},{"year":1995,"finding":"Growth hormone induces CEBPD at the transcriptional level (increased mRNA superinducible by cycloheximide) in 3T3-F442A preadipocytes, distinct from its translational activation of C/EBPβ; this induction is not observed with insulin.","method":"EMSA, Western blot, Northern blot, pharmacological inhibitors of JAK2 and protein kinase C","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods in a single study distinguishing transcriptional from translational mechanisms","pmids":["7760844"],"is_preprint":false},{"year":1996,"finding":"VIP, PACAP, and noradrenaline induce CEBPD expression in cortical astrocytes via the cAMP second-messenger pathway; CEBPD behaves as a cAMP-inducible immediate-early gene, and forced expression of CEBPD enhances glycogen resynthesis in astrocytes.","method":"Northern blot, protein synthesis inhibitor assays, transfection with expression vectors measuring glycogen resynthesis","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — immediate-early gene evidence plus functional rescue via CEBPD overexpression","pmids":["8558260"],"is_preprint":false},{"year":1997,"finding":"CEBPD expression is induced in mammary epithelial cells (COMMA D) arrested in G0 by serum/growth factor withdrawal or contact inhibition; antisense-mediated loss of CEBPD markedly delays growth arrest, establishing a role for CEBPD in G0 arrest.","method":"Northern blot, Western blot, EMSA, antisense construct transfection, BrdU incorporation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with antisense plus multiple molecular readouts in a single study","pmids":["9045647"],"is_preprint":false},{"year":2000,"finding":"CEBPD and C/EBPα transactivate the CYP2B1 promoter in lung epithelial cells; a proximal C/EBP-binding site in the CYP2B1 promoter is necessary for this transactivation, as shown by site-directed mutagenesis.","method":"Transient transfection reporter assay, EMSA, site-directed mutagenesis","journal":"Molecular cell biology research communications","confidence":"Medium","confidence_rationale":"Tier 1-2 — mutagenesis plus functional reporter assay","pmids":["10683316"],"is_preprint":false},{"year":2001,"finding":"CEBPD is essential for the second (de novo protein synthesis-dependent) phase of LPS-induced COX-2 mRNA induction in macrophages; C/EBPβ-knockout macrophages are defective in both phases, and CEBPD synthesis is induced by LPS in a MAPK/SAPK2/p38-dependent manner.","method":"C/EBPβ-knockout macrophages, pharmacological inhibition of MAPK and p38 cascades, Northern blot, Western blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout model combined with pharmacological pathway dissection","pmids":["11668179"],"is_preprint":false},{"year":2003,"finding":"CEBPD protein levels are short-lived in G0-arrested mammary epithelial cells (t½ ~120 min); C/EBPδ protein is degraded in a ubiquitin-dependent manner, primarily in the nucleus, during G0 growth arrest.","method":"Protein half-life assays with translation inhibitors, ubiquitin-dependent proteasome inhibitor assays, nuclear/cytoplasmic fractionation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological evidence for ubiquitin-dependent nuclear degradation with multiple inhibitors","pmids":["12554732"],"is_preprint":false},{"year":2005,"finding":"IL-1β regulates CEBPD transcriptional activity through p38 MAP kinase; a docking site for p38 MAPK located between amino acids 75–85 is necessary for CEBPD phosphorylation, and a transactivation domain between amino acids 70–108 is required for IL-1-dependent haptoglobin induction and p300-dependent transactivation.","method":"p38 kinase inhibitor (SB203580), deletion mutagenesis, transient transfection reporter assay, Northern blot","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis mapping of kinase docking site and transactivation domain with functional validation","pmids":["15694370"],"is_preprint":false},{"year":2007,"finding":"ΔNp63α represses CEBPD expression in keratinocytes; CEBPD in turn binds to and activates the ΔNp63 promoter, establishing a reciprocal regulatory loop; CEBPD is found on p63 target gene promoters in vivo by ChIP analysis.","method":"RNAi screening, RT-PCR, ChIP, reporter assay, overexpression and inactivation studies","journal":"BMC molecular biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal regulation validated by ChIP and functional reporter assay with siRNA knockdown","pmids":["17903252"],"is_preprint":false},{"year":2008,"finding":"CEBPD is sumoylated at lysine 120 by SUMO1; sumoylated CEBPD recruits HDAC1 and HDAC3 to the PPARG2 promoter to inactivate transcription, while non-sumoylated CEBPD acts as an activator; identified two CEBPD-binding motifs on the PPARG2 promoter at −324/−311 and −158/−145.","method":"5'-serial deletion reporter analysis, site-directed mutagenesis of CEBPD binding sites, in vivo ChIP, sumoylation mutant constructs","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1-2 — SUMO modification identified, functional consequences dissected via mutagenesis and ChIP in a single study","pmids":["18619497"],"is_preprint":false},{"year":2010,"finding":"CEBPD induces expression of the CDC27/APC3 subunit of the APC/C complex, leading to polyubiquitination and proteasomal degradation of cyclin D1; CEBPD also down-regulates cyclin B1, Skp2, and Plk-1; in CEBPD knockout MEFs, Cdc27 levels are reduced and cyclin D1 levels are elevated.","method":"CEBPD knockout MEF analysis, siRNA silencing, Western blot, co-immunoprecipitation/ubiquitination assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — knockout and siRNA combined with mechanistic ubiquitination assays across multiple cell types","pmids":["20439707"],"is_preprint":false},{"year":2010,"finding":"CEBPD physically interacts with FANCD2 and importin 4 (IPO4) via separate domains, mediating FANCD2-IPO4 association and augmenting nuclear import of FANCD2; this promotes FANCD2 monoubiquitination required for DNA repair; this is a transcription-independent function of CEBPD.","method":"Co-immunoprecipitation, gene knockout, protein overexpression/depletion, nuclear import assays, FANCD2 monoubiquitination assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with multiple domains, genetic knockout, and functional monoubiquitination readout","pmids":["20805509"],"is_preprint":false},{"year":2010,"finding":"CEBPD induces expression of PTX3 (pentraxin-3) in astrocytes, and PTX3 participates in attenuating macrophage-mediated phagocytosis of damaged neuron cells, establishing an astrocyte CEBPD→PTX3 axis in neuroinflammation.","method":"Global gene expression profiling, reporter assays, siRNA knockdown, phagocytosis functional assays","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2-3 — gene expression profiling plus functional phagocytosis assay, single lab","pmids":["21112127"],"is_preprint":false},{"year":2010,"finding":"CEBPD directly transactivates the SOD1 promoter, reducing cisplatin-induced reactive oxygen species and apoptosis in bladder carcinoma cells, conferring drug resistance.","method":"Reporter assay, ChIP, siRNA knockdown, ROS measurement, apoptosis assay","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter transactivation confirmed by ChIP plus functional ROS/apoptosis readout","pmids":["20385105"],"is_preprint":false},{"year":2010,"finding":"CEBPD and STAT-1 are required for basal and R848-stimulated transcriptional activity of the human TLR8 promoter; CEBPD binds three C/EBP cis-acting elements in the TLR8 promoter, with enhanced binding upon R848 stimulation.","method":"Luciferase reporter assay, ChIP assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay combined with ChIP confirmation of CEBPD binding","pmids":["20829351"],"is_preprint":false},{"year":2011,"finding":"CEBPD inhibits prolactin (PRL) expression by binding to the PRL promoter and suppressing PRL promoter activity (96% suppression); CEBPD physically interacts with Pit1 and attenuates each other's binding to the PRL promoter; CEBPD also suppresses c-Myc, survivin, and cyclins B1, B2, and D1 expression.","method":"ChIP, luciferase reporter assay, co-immunoprecipitation, siRNA knockdown, microarray gene expression profiling","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — ChIP combined with Co-IP and functional reporter assay showing CEBPD-Pit1 interaction at PRL promoter","pmids":["21980073"],"is_preprint":false},{"year":2011,"finding":"CEBPD regulates VEGF-C and VEGFR3 expression in lymphatic endothelial cells (LECs) to drive lymphangiogenesis; CEBPD expression is induced by hypoxia, and CEBPD regulates HIF-1α which in turn mediates VEGF-C and VEGFR3 upregulation; genetic deletion of CEBPD in mice reduces lymphangiogenesis and pulmonary metastases.","method":"CEBPD knockout mice, forced expression and knockdown in LECs, in vitro migration and network formation assays, Western blot, reporter assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — in vivo knockout mouse model combined with in vitro gain/loss-of-function and mechanistic pathway dissection","pmids":["21666710"],"is_preprint":false},{"year":2012,"finding":"CEBPD has anti-apoptotic and anti-inflammatory roles in pancreatic β-cells; CEBPD deficiency exacerbates cytokine-induced apoptosis through increased CHOP and BIM expression; CEBPD deficiency boosts chemokine production (CXCL1, 9, 10, CCL20) by hampering IRF-1 upregulation and increasing STAT1 activation.","method":"siRNA knockdown, double knockdown epistasis, overexpression, caspase cleavage assays, ELISA for chemokines","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — double knockdown epistasis establishing pathway order, combined with gain-of-function rescue experiments","pmids":["22347430"],"is_preprint":false},{"year":2013,"finding":"The transcription factor Miz1 terminates LPS-induced inflammation by repressing CEBPD transcription; after LPS stimulation, Miz1 is phosphorylated at Ser178, which is required for recruitment of HDAC1 to repress the CEBPD gene, thereby limiting proinflammatory cytokine expression.","method":"Genetic disruption of Miz1 POZ domain in mice, Miz1 Ser178 mutagenesis, HDAC1 co-immunoprecipitation/ChIP, cytokine measurement","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo mouse genetic model combined with phosphorylation site mutagenesis and HDAC1 recruitment assays","pmids":["23525087"],"is_preprint":false},{"year":2016,"finding":"CEBPD expression is induced by cisplatin through the EGFR/STAT3 pathway in bladder carcinoma cells; CEBPD then directly activates ABCB1 and ABCC2 drug transporter genes, conferring cross-resistance to paclitaxel; inhibition of EGFR or STAT3 reverses this resistance.","method":"siRNA loss-of-function, reporter assay, ChIP, xenograft animal assay, EGFR/STAT3 inhibitors","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 — ChIP-confirmed direct CEBPD binding to ABCB1/ABCC2 promoters, validated in vivo with xenografts","pmids":["27435393"],"is_preprint":false},{"year":2019,"finding":"DN-ATF5 associates in cells with CEBPB and CEBPD (and CCDC6) via leucine zipper interactions, blocking formation of transcriptionally active CEBPB and CEBPD homodimers and heterodimers; CEBPB or CEBPD knockdown promotes apoptosis in cancer cells but not normal astrocytes.","method":"Unbiased pull-down with mass spectrometry, immunoblotting, siRNA knockdown, transcriptional activity assays","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 2 — unbiased MS-based pull-down combined with functional siRNA knockdown across multiple cell lines","pmids":["31676720"],"is_preprint":false},{"year":2020,"finding":"IPO4 (importin 4) augments nuclear translocation of CEBPD through nuclear localization signals (NLS); nuclear CEBPD then transcriptionally upregulates PRKDC (DNA-PKcs), activating DNA damage repair; cisplatin treatment strengthens CEBPD transcriptional activity toward PRKDC.","method":"shRNA knockdown, reporter assay, nuclear fractionation, in vivo xenograft, loss-of-function assays in cervical cancer cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway (IPO4→CEBPD nuclear import→PRKDC transcription) established by multiple functional assays","pmids":["32661323"],"is_preprint":false},{"year":2020,"finding":"SUMOylation of PUM2 (by UBE2I/SUMO2/3) decreases the ability of PUM2 to inhibit CEBPD mRNA stability; elevated CEBPD then binds the DSG2 promoter to upregulate DSG2, promoting vasculogenic mimicry in glioma cells.","method":"Co-IP, immunofluorescence, RNA immunoprecipitation (RIP), ChIP, luciferase assay, 3D cell culture VM assay","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (RIP, ChIP, Co-IP) establishing the UBE2I/PUM2/CEBPD/DSG2 axis","pmids":["32997416"],"is_preprint":false},{"year":2021,"finding":"BRD4 controls CEBPD expression via its bromodomain-1 (not bromodomain-2) by binding a H3K27ac-marked enhancer at the Cebpd locus; BRD4 and CEBPD proteins physically co-immunoprecipitate and co-occupy the Cebpd promoter and enhancer DNA, forming a BRD4/CEBPD/promoter/enhancer complex that is disrupted by JQ1.","method":"ChIP-seq, genomic enhancer deletion, siRNA silencing, reciprocal Co-IP, BRD4 bromodomain-specific constructs","journal":"Molecular therapy. Methods & clinical development","confidence":"High","confidence_rationale":"Tier 2 — ChIP-seq, reciprocal Co-IP, and enhancer deletion combined with bromodomain-specific dissection in a single study","pmids":["33768129"],"is_preprint":false},{"year":2021,"finding":"Deletion of the CEBPD transactivation domain (ΔTAD) reveals that the context-dependent role of CEBPD in macrophage cytokine production depends on compensatory transcriptional activity; CRISPR-generated ΔTAD macrophages reveal a large discrepancy between transcriptional programs in CEBPD knockout vs. CEBPD-ΔTAD macrophages.","method":"CRISPR-Cas9 endogenous TAD deletion, RNA-seq comparison of KO vs. ΔTAD macrophages, LPS stimulation assays","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR-generated separation-of-function allele with transcriptomic comparison, single lab","pmids":["34571881"],"is_preprint":false},{"year":2023,"finding":"In glioblastoma, HIF1α and HIF2α activate the CEBPD promoter under hypoxia; CEBPD in turn directly binds and activates the FN1 (fibronectin) promoter; FN1 and its integrin receptors mediate CEBPD-induced EGFR phosphorylation and PI3K pathway activation, promoting invasion.","method":"Proteomic analysis, TF binding analysis, HIF1α/HIF2α overexpression, ChIP-qPCR/ChIP-seq, luciferase reporter assay, Western blot","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP-seq and luciferase reporter validating direct CEBPD binding to FN1 promoter, mechanistic pathway established","pmids":["37059730"],"is_preprint":false},{"year":2024,"finding":"CEBPD acts as a key transcription factor in IL-21-engineered NK cells; deletion of CEBPD reduces IL-21 NK cell cytotoxicity and metabolic fitness, while overexpression enhances long-term anti-tumor activity, placing CEBPD downstream of IL-21 signaling in NK cell functional reprogramming.","method":"CEBPD deletion and overexpression in NK cells, chromatin accessibility (ATAC-seq), in vivo GBM models, cytotoxicity and metabolic assays","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — loss- and gain-of-function combined with chromatin accessibility sequencing and in vivo models","pmids":["39137729"],"is_preprint":false}],"current_model":"CEBPD is an inducible bZIP transcription factor that forms homodimers and heterodimers (notably with C/EBPβ and Pit1) to directly transactivate or repress target gene promoters (including C3, COX-2, TLR8, PRL, SOD1, ABCB1/C2, FN1, VEGFR2, CDC27/APC3, PRKDC); its activity is modulated post-translationally by p38 MAPK-mediated phosphorylation, SUMO1 modification at K120 (recruiting HDAC1/3 for repression), and ubiquitin-dependent nuclear proteasomal degradation; it also performs transcription-independent functions by scaffolding FANCD2–importin 4 complexes to promote nuclear import and monoubiquitination of FANCD2 in DNA damage repair; CEBPD expression is controlled upstream by IL-1/IL-6/LPS signaling, cAMP pathway activation, EGFR/STAT3 signaling, BRD4 enhancer activity, and negative regulation by Miz1-HDAC1-mediated transcriptional repression."},"narrative":{"teleology":[{"year":1992,"claim":"Establishing that CEBPD heterodimerizes with C/EBPβ and that the heterodimer binds the same DNA elements as homodimers resolved the fundamental question of how the C/EBP family achieves combinatorial transcriptional control.","evidence":"In vitro heterodimerization, EMSA, and luciferase reporter assays","pmids":["1741402"],"confidence":"High","gaps":["Stoichiometry and relative affinity of heterodimer vs. homodimer at endogenous promoters unknown","In vivo relevance of heterodimerization not demonstrated"]},{"year":1993,"claim":"Demonstrating that CEBPD is the principal IL-1- and IL-6-inducible C/EBP family member that transactivates acute-phase gene promoters (C3, hemopexin, haptoglobin, CRP) established CEBPD as the effector linking cytokine signaling to the hepatic acute-phase response.","evidence":"Supershift EMSA, Western blot of nuclear accumulation, and reporter assays in Hep3B hepatoma cells after IL-1 or IL-6 treatment","pmids":["8385337","7680115"],"confidence":"High","gaps":["Contribution of CEBPD relative to C/EBPβ at endogenous acute-phase loci not quantified","In vivo acute-phase response in CEBPD-null animals not yet tested at this stage"]},{"year":1995,"claim":"Identifying that CEBPD synergizes with PU.1 via direct leucine-zipper-to-Ets-domain contact, and that growth hormone transcriptionally induces CEBPD independently of insulin, broadened the upstream signals and cooperative partners controlling CEBPD activity.","evidence":"Far Western, deletion mutagenesis, EMSA, and synergy reporter assay for PU.1; Northern blot with cycloheximide superinduction for GH induction","pmids":["7594592","7760844"],"confidence":"High","gaps":["Genomic targets co-regulated by CEBPD–PU.1 not identified","Signaling intermediates between GH receptor and CEBPD promoter not mapped"]},{"year":1996,"claim":"Showing that CEBPD behaves as a cAMP-inducible immediate-early gene in astrocytes and that its forced expression enhances glycogen resynthesis established a metabolic effector role outside the immune system.","evidence":"Northern blot with protein synthesis inhibitors and CEBPD overexpression glycogen resynthesis assay in cortical astrocytes","pmids":["8558260"],"confidence":"High","gaps":["Direct target genes mediating glycogen resynthesis not identified","In vivo brain metabolic phenotype of CEBPD loss not tested"]},{"year":1997,"claim":"Demonstrating that CEBPD is induced during G0 arrest and that antisense-mediated loss delays growth arrest provided the first functional evidence that CEBPD is required for cell cycle exit.","evidence":"Antisense knockdown, BrdU incorporation, Northern/Western blot in mammary epithelial cells","pmids":["9045647"],"confidence":"High","gaps":["Direct transcriptional targets mediating G0 arrest unknown at this point","Mechanism distinguishing CEBPD from C/EBPα in growth arrest not resolved"]},{"year":2003,"claim":"Revealing that CEBPD protein has a short half-life (~120 min) and is degraded by ubiquitin-dependent nuclear proteasomal pathways during G0 explained how CEBPD protein levels are dynamically controlled despite ongoing transcription.","evidence":"Translation inhibitor chase, proteasome inhibitors, nuclear/cytoplasmic fractionation in mammary epithelial cells","pmids":["12554732"],"confidence":"Medium","gaps":["E3 ubiquitin ligase responsible for CEBPD degradation not identified","Ubiquitination sites on CEBPD not mapped"]},{"year":2005,"claim":"Mapping a p38 MAPK docking site (aa 75–85) and a transactivation domain (aa 70–108) on CEBPD that are required for IL-1-dependent gene activation resolved how inflammatory signaling post-translationally enhances CEBPD transcriptional potency.","evidence":"Deletion mutagenesis, p38 inhibitor SB203580, reporter assays, Northern blot in hepatoma cells","pmids":["15694370"],"confidence":"High","gaps":["Specific phosphorylation sites on CEBPD targeted by p38 not identified by mass spectrometry","Whether p38 phosphorylation alters CEBPD protein stability not tested"]},{"year":2008,"claim":"Discovering that SUMO1 modification at K120 converts CEBPD from a transcriptional activator to a repressor by recruiting HDAC1/3 (demonstrated at the PPARγ2 promoter) established a post-translational switch mechanism governing CEBPD's dual activator/repressor functions.","evidence":"SUMOylation mutant constructs, ChIP for HDAC1/3 recruitment, serial deletion and site-directed mutagenesis of PPARγ2 promoter","pmids":["18619497"],"confidence":"High","gaps":["Signals that control the balance between sumoylated and non-sumoylated CEBPD unknown","Genome-wide identification of SUMO-dependent CEBPD repression targets not performed"]},{"year":2010,"claim":"A burst of studies in 2010 established multiple new CEBPD functions: transcriptional activation of CDC27/APC3 leading to cyclin D1 degradation (linking CEBPD to cell cycle control via the APC/C), direct transactivation of SOD1 conferring cisplatin resistance, regulation of TLR8 transcription, induction of PTX3 in neuroinflammation, and — critically — a transcription-independent scaffolding role bridging FANCD2 and importin 4 for DNA damage repair.","evidence":"CEBPD knockout MEFs, siRNA, ubiquitination assays for CDC27/cyclin D1; ChIP and ROS assays for SOD1; ChIP for TLR8; reciprocal Co-IP, nuclear import assays, and FANCD2 monoubiquitination readouts for the scaffolding function","pmids":["20439707","20385105","20829351","20805509","21112127"],"confidence":"High","gaps":["Structural basis of the CEBPD–FANCD2–IPO4 ternary complex not determined","Relative importance of transcription-dependent vs. -independent CEBPD functions in DNA damage response unclear","Whether CEBPD scaffolding role extends to other Fanconi pathway substrates unknown"]},{"year":2011,"claim":"Identifying CEBPD as a repressor of prolactin expression through physical interaction with Pit1, and as a regulator of VEGF-C/VEGFR3-driven lymphangiogenesis via HIF-1α, expanded CEBPD's roles to endocrine regulation and tumor-associated vascular remodeling.","evidence":"ChIP, Co-IP of CEBPD–Pit1, reporter assays for PRL; CEBPD knockout mice showing reduced lymphangiogenesis and metastasis","pmids":["21980073","21666710"],"confidence":"High","gaps":["CEBPD–Pit1 interaction interface not structurally resolved","Whether CEBPD-dependent lymphangiogenesis operates independently of its cell-cycle arrest functions unclear"]},{"year":2013,"claim":"Demonstrating that Miz1 terminates LPS-induced inflammation by recruiting HDAC1 to repress CEBPD transcription (dependent on Miz1 Ser178 phosphorylation) identified a key negative feedback mechanism that limits CEBPD-driven inflammatory gene expression.","evidence":"Miz1 POZ domain disruption in mice, Ser178 mutagenesis, HDAC1 ChIP at CEBPD promoter, cytokine measurements","pmids":["23525087"],"confidence":"High","gaps":["Kinase responsible for Miz1 Ser178 phosphorylation not identified","Whether other C/EBP family members are similarly repressed by Miz1 not addressed"]},{"year":2016,"claim":"Showing that cisplatin induces CEBPD through the EGFR/STAT3 axis and that CEBPD directly activates ABCB1 and ABCC2 drug transporter genes established CEBPD as a mediator of chemotherapy cross-resistance, validated in xenograft models.","evidence":"ChIP at ABCB1/ABCC2 promoters, siRNA, EGFR/STAT3 inhibitors, xenograft assays in bladder carcinoma","pmids":["27435393"],"confidence":"High","gaps":["Whether CEBPD-mediated drug resistance operates in tumor types beyond bladder carcinoma not tested","Contribution of CEBPD vs. other transcription factors to ABCB1 induction not quantified"]},{"year":2021,"claim":"Discovering that BRD4 controls CEBPD expression through bromodomain-1-dependent binding to an H3K27ac-marked enhancer, and that BRD4 and CEBPD physically interact and co-occupy the Cebpd locus, revealed an epigenetic feedforward loop governing CEBPD transcription that is pharmacologically targetable by JQ1.","evidence":"ChIP-seq, enhancer deletion, reciprocal Co-IP, bromodomain-specific constructs, JQ1 disruption","pmids":["33768129"],"confidence":"High","gaps":["Whether the BRD4–CEBPD loop operates genome-wide at other CEBPD target genes not established","Contribution of BRD4 BD1 vs. BD2 at other C/EBP family gene loci unknown"]},{"year":2023,"claim":"Demonstrating that HIF1α/HIF2α activate the CEBPD promoter under hypoxia and that CEBPD directly binds and activates the FN1 promoter to drive EGFR/PI3K-mediated glioblastoma invasion established a hypoxia→CEBPD→FN1→integrin signaling axis in tumor progression.","evidence":"ChIP-seq, ChIP-qPCR, luciferase reporter, HIF overexpression, proteomic and Western blot analyses in glioblastoma cells","pmids":["37059730"],"confidence":"High","gaps":["Whether the HIF–CEBPD–FN1 axis operates in non-CNS hypoxic tumors not tested","Relative contribution of HIF1α vs. HIF2α to CEBPD induction not quantified"]},{"year":2024,"claim":"Identifying CEBPD as a key downstream effector of IL-21 signaling in NK cells — where its deletion reduces cytotoxicity and metabolic fitness and its overexpression enhances long-term anti-tumor activity — placed CEBPD as a functional reprogramming factor in innate immune effector cells.","evidence":"CEBPD deletion and overexpression in NK cells, ATAC-seq, in vivo GBM models, cytotoxicity and metabolic assays","pmids":["39137729"],"confidence":"High","gaps":["Direct transcriptional targets of CEBPD in NK cells not catalogued","Whether CEBPD operates similarly in other innate lymphoid cell subsets not tested"]},{"year":null,"claim":"Despite extensive characterization of CEBPD's transcriptional targets and post-translational regulation, several core mechanistic questions remain: the E3 ligase(s) mediating CEBPD ubiquitin-dependent degradation, the structural basis of the CEBPD–FANCD2–IPO4 scaffolding complex, the genome-wide map of SUMO-dependent CEBPD repression targets, and the signals controlling the activator-to-repressor switch via SUMOylation are unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["E3 ubiquitin ligase for CEBPD not identified","No structural model of CEBPD in any complex","Genome-wide SUMO-dependent repression targets not mapped","Integration of transcription-dependent and -independent CEBPD functions in DNA damage not modeled"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,2,13,18,19,29]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,2,8,13,14,17,19,23,29,30]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[15]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,10,15,25]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,18,22,30]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[15,25]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[7,14]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[21,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,20,23]}],"complexes":[],"partners":["CEBPB","PU.1","FANCD2","IPO4","HDAC1","BRD4","PIT1","ATF5"],"other_free_text":[]},"mechanistic_narrative":"CEBPD is an inducible bZIP transcription factor that functions as a central integrator of inflammatory, growth-arrest, and stress-responsive gene programs by forming homodimers and heterodimers with C/EBPβ, PU.1, and Pit1 to activate or repress diverse target promoters including C3, COX-2, TLR8, PRL, SOD1, ABCB1/ABCC2, FN1, CDC27/APC3, and PRKDC [PMID:1741402, PMID:8385337, PMID:20439707, PMID:27435393, PMID:37059730]. Its transcriptional activity is tightly modulated by p38 MAPK-mediated phosphorylation at a docking site between residues 75–85, SUMO1 modification at K120 that switches CEBPD from an activator to a repressor by recruiting HDAC1/3, and ubiquitin-dependent nuclear proteasomal degradation [PMID:15694370, PMID:18619497, PMID:12554732]. Beyond transcription, CEBPD performs a scaffolding function by bridging FANCD2 and importin 4 to promote FANCD2 nuclear import and monoubiquitination required for DNA damage repair [PMID:20805509]. CEBPD expression is controlled upstream by IL-1/IL-6/LPS, cAMP, EGFR/STAT3, hypoxia/HIF, and BRD4-dependent enhancer activity, and is terminated by Miz1-HDAC1-mediated transcriptional repression [PMID:8385337, PMID:7680115, PMID:23525087, PMID:33768129, PMID:37059730]."},"prefetch_data":{"uniprot":{"accession":"P49716","full_name":"CCAAT/enhancer-binding protein delta","aliases":["Nuclear factor NF-IL6-beta","NF-IL6-beta"],"length_aa":269,"mass_kda":28.5,"function":"Transcription activator that recognizes two different DNA motifs: the CCAAT homology common to many promoters and the enhanced core homology common to many enhancers (PubMed:16397300). Important transcription factor regulating the expression of genes involved in immune and inflammatory responses (PubMed:16397300, PubMed:1741402). Transcriptional activator that enhances IL6 transcription alone and as heterodimer with CEBPB (PubMed:1741402)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P49716/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CEBPD","classification":"Not Classified","n_dependent_lines":30,"n_total_lines":1208,"dependency_fraction":0.024834437086092714},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CEBPD","total_profiled":1310},"omim":[{"mim_id":"612455","title":"SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 12; SLC5A12","url":"https://www.omim.org/entry/612455"},{"mim_id":"608044","title":"SOLUTE CARRIER FAMILY 5 (IODIDE TRANSPORTER), MEMBER 8; SLC5A8","url":"https://www.omim.org/entry/608044"},{"mim_id":"608004","title":"NUCLEAR FACTOR KAPPA-B INHIBITOR, ZETA; NFKBIZ","url":"https://www.omim.org/entry/608004"},{"mim_id":"607096","title":"SOLUTE CARRIER FAMILY 22 (URATE TRANSPORTER), MEMBER 12; SLC22A12","url":"https://www.omim.org/entry/607096"},{"mim_id":"607043","title":"TRAF3-INTERACTING PROTEIN 2; TRAF3IP2","url":"https://www.omim.org/entry/607043"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CEBPD"},"hgnc":{"alias_symbol":["CRP3","CELF","C/EBP-delta","NF-IL6-beta"],"prev_symbol":[]},"alphafold":{"accession":"P49716","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49716","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49716-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49716-F1-predicted_aligned_error_v6.png","plddt_mean":65.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CEBPD","jax_strain_url":"https://www.jax.org/strain/search?query=CEBPD"},"sequence":{"accession":"P49716","fasta_url":"https://rest.uniprot.org/uniprotkb/P49716.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49716/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49716"}},"corpus_meta":[{"pmid":"19075228","id":"PMC_19075228","title":"A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19075228","citation_count":426,"is_preprint":false},{"pmid":"11158314","id":"PMC_11158314","title":"The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11158314","citation_count":368,"is_preprint":false},{"pmid":"1741402","id":"PMC_1741402","title":"A member of the C/EBP family, NF-IL6 beta, forms a heterodimer and transcriptionally synergizes with NF-IL6.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1741402","citation_count":313,"is_preprint":false},{"pmid":"22180311","id":"PMC_22180311","title":"The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins.","date":"2011","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/22180311","citation_count":194,"is_preprint":false},{"pmid":"25883322","id":"PMC_25883322","title":"Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins.","date":"2015","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/25883322","citation_count":161,"is_preprint":false},{"pmid":"7680115","id":"PMC_7680115","title":"The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms.","date":"1993","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/7680115","citation_count":161,"is_preprint":false},{"pmid":"20220144","id":"PMC_20220144","title":"Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C/EBP-beta nor C/EBP-delta.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20220144","citation_count":133,"is_preprint":false},{"pmid":"8385337","id":"PMC_8385337","title":"Participation of the transcription factor C/EBP delta in the acute-phase regulation of the human gene for complement component C3.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8385337","citation_count":132,"is_preprint":false},{"pmid":"16480813","id":"PMC_16480813","title":"Mammalian CELF/Bruno-like RNA-binding proteins: molecular characteristics and biological functions.","date":"2005","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/16480813","citation_count":127,"is_preprint":false},{"pmid":"11668179","id":"PMC_11668179","title":"The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein beta (C/EBP beta ) and C/EBP delta transcription factors.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11668179","citation_count":124,"is_preprint":false},{"pmid":"8981979","id":"PMC_8981979","title":"The processive endocellulase CelF, a major component of the Clostridium cellulolyticum cellulosome: purification and characterization of the recombinant form.","date":"1997","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/8981979","citation_count":113,"is_preprint":false},{"pmid":"7594592","id":"PMC_7594592","title":"Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7594592","citation_count":95,"is_preprint":false},{"pmid":"12649496","id":"PMC_12649496","title":"Antagonistic regulation of alpha-actinin alternative splicing by CELF proteins and polypyrimidine tract binding protein.","date":"2003","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12649496","citation_count":92,"is_preprint":false},{"pmid":"8558260","id":"PMC_8558260","title":"Vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, and noradrenaline induce the transcription factors CCAAT/enhancer binding protein (C/EBP)-beta and C/EBP delta in mouse cortical astrocytes: involvement in cAMP-regulated glycogen metabolism.","date":"1996","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/8558260","citation_count":90,"is_preprint":false},{"pmid":"7760844","id":"PMC_7760844","title":"Early responses of trans-activating factors to growth hormone in preadipocytes: differential regulation of CCAAT enhancer-binding protein-beta (C/EBP beta) and C/EBP delta.","date":"1995","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/7760844","citation_count":81,"is_preprint":false},{"pmid":"19720736","id":"PMC_19720736","title":"MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1.","date":"2009","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19720736","citation_count":80,"is_preprint":false},{"pmid":"14761971","id":"PMC_14761971","title":"CELF6, a member of the CELF family of RNA-binding proteins, regulates muscle-specific splicing enhancer-dependent alternative splicing.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14761971","citation_count":77,"is_preprint":false},{"pmid":"9045647","id":"PMC_9045647","title":"CCAAT/enhancer-binding protein-delta (C/EBP-delta) is induced in growth-arrested mouse mammary epithelial cells.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9045647","citation_count":76,"is_preprint":false},{"pmid":"21112127","id":"PMC_21112127","title":"CCAAT/enhancer binding protein delta (CEBPD) elevating PTX3 expression inhibits macrophage-mediated phagocytosis of dying neuron cells.","date":"2010","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/21112127","citation_count":73,"is_preprint":false},{"pmid":"23525087","id":"PMC_23525087","title":"Suppression of inflammation and acute lung injury by Miz1 via repression of C/EBP-δ.","date":"2013","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23525087","citation_count":71,"is_preprint":false},{"pmid":"18971639","id":"PMC_18971639","title":"Posttranscriptional regulation of gene networks by GU-rich elements and CELF proteins.","date":"2008","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/18971639","citation_count":70,"is_preprint":false},{"pmid":"15988035","id":"PMC_15988035","title":"Cardiac tissue-specific repression of CELF activity disrupts alternative splicing and causes cardiomyopathy.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15988035","citation_count":68,"is_preprint":false},{"pmid":"21666710","id":"PMC_21666710","title":"C/EBP-δ regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1α.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21666710","citation_count":67,"is_preprint":false},{"pmid":"20439707","id":"PMC_20439707","title":"C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20439707","citation_count":65,"is_preprint":false},{"pmid":"39137729","id":"PMC_39137729","title":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD.","date":"2024","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/39137729","citation_count":62,"is_preprint":false},{"pmid":"23247071","id":"PMC_23247071","title":"CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.","date":"2012","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/23247071","citation_count":60,"is_preprint":false},{"pmid":"12865412","id":"PMC_12865412","title":"Keratinocyte growth factor and the transcription factors C/EBP alpha, C/EBP delta, and SREBP-1c regulate fatty acid synthesis in alveolar type II cells.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12865412","citation_count":58,"is_preprint":false},{"pmid":"28099155","id":"PMC_28099155","title":"Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28099155","citation_count":57,"is_preprint":false},{"pmid":"20385105","id":"PMC_20385105","title":"Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells.","date":"2010","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20385105","citation_count":57,"is_preprint":false},{"pmid":"27435393","id":"PMC_27435393","title":"Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27435393","citation_count":55,"is_preprint":false},{"pmid":"22347430","id":"PMC_22347430","title":"The transcription factor C/EBP delta has anti-apoptotic and anti-inflammatory roles in pancreatic beta cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22347430","citation_count":54,"is_preprint":false},{"pmid":"37059730","id":"PMC_37059730","title":"CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37059730","citation_count":52,"is_preprint":false},{"pmid":"11916518","id":"PMC_11916518","title":"C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies.","date":"2002","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/11916518","citation_count":50,"is_preprint":false},{"pmid":"28512194","id":"PMC_28512194","title":"Ancient antagonism between CELF and RBFOX families tunes mRNA splicing outcomes.","date":"2017","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/28512194","citation_count":49,"is_preprint":false},{"pmid":"23416545","id":"PMC_23416545","title":"Position-dependent and neuron-specific splicing regulation by the CELF family RNA-binding protein UNC-75 in Caenorhabditis elegans.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/23416545","citation_count":47,"is_preprint":false},{"pmid":"27502555","id":"PMC_27502555","title":"Conserved functional antagonism of CELF and MBNL proteins controls stem cell-specific alternative splicing in planarians.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27502555","citation_count":46,"is_preprint":false},{"pmid":"18619497","id":"PMC_18619497","title":"HDAC1/HDAC3 modulates PPARG2 transcription through the sumoylated CEBPD in hepatic lipogenesis.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18619497","citation_count":46,"is_preprint":false},{"pmid":"10572139","id":"PMC_10572139","title":"Cellobiose-6-phosphate hydrolase (CelF) of Escherichia coli: characterization and assignment to the unusual family 4 of glycosylhydrolases.","date":"1999","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/10572139","citation_count":46,"is_preprint":false},{"pmid":"20971808","id":"PMC_20971808","title":"CEBPD reverses RB/E2F1-mediated gene repression and participates in HMDB-induced apoptosis of cancer cells.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20971808","citation_count":44,"is_preprint":false},{"pmid":"15894795","id":"PMC_15894795","title":"Identification of CELF splicing activation and repression domains in vivo.","date":"2005","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15894795","citation_count":41,"is_preprint":false},{"pmid":"8936327","id":"PMC_8936327","title":"Molecular study and overexpression of the Clostridium cellulolyticum celF cellulase gene in Escherichia coli.","date":"1996","source":"Microbiology (Reading, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8936327","citation_count":40,"is_preprint":false},{"pmid":"23468662","id":"PMC_23468662","title":"CELF family RNA-binding protein UNC-75 regulates two sets of mutually exclusive exons of the unc-32 gene in neuron-specific manners in Caenorhabditis elegans.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23468662","citation_count":39,"is_preprint":false},{"pmid":"8650608","id":"PMC_8650608","title":"Effect of thermal injury on the expression of transcription factors that regulate acute phase response genes: the response of C/EBP alpha, C/EBP beta, and C/EBP delta to thermal injury.","date":"1996","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/8650608","citation_count":38,"is_preprint":false},{"pmid":"31676720","id":"PMC_31676720","title":"Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/31676720","citation_count":37,"is_preprint":false},{"pmid":"20622515","id":"PMC_20622515","title":"The role of CELF proteins in neurological disorders.","date":"2010","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/20622515","citation_count":36,"is_preprint":false},{"pmid":"20805509","id":"PMC_20805509","title":"CCAAT/enhancer binding protein delta (C/EBPdelta, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20805509","citation_count":35,"is_preprint":false},{"pmid":"32997416","id":"PMC_32997416","title":"SUMOylation of PUM2 promotes the vasculogenic mimicry of glioma cells via regulating CEBPD.","date":"2020","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32997416","citation_count":33,"is_preprint":false},{"pmid":"1805307","id":"PMC_1805307","title":"Nucleotide sequence of the cellulase gene celF of Clostridium thermocellum.","date":"1991","source":"Research in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/1805307","citation_count":33,"is_preprint":false},{"pmid":"19854948","id":"PMC_19854948","title":"The neurofibromatosis type I pre-mRNA is a novel target of CELF protein-mediated splicing regulation.","date":"2009","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19854948","citation_count":32,"is_preprint":false},{"pmid":"8314590","id":"PMC_8314590","title":"The human C/EBP delta (CRP3/CELF) gene: structure and chromosomal localization.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8314590","citation_count":32,"is_preprint":false},{"pmid":"25771860","id":"PMC_25771860","title":"ROCK2 promotes HCC proliferation by CEBPD inhibition through phospho-GSK3β/β-catenin signaling.","date":"2015","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/25771860","citation_count":31,"is_preprint":false},{"pmid":"20829351","id":"PMC_20829351","title":"C/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20829351","citation_count":31,"is_preprint":false},{"pmid":"21492414","id":"PMC_21492414","title":"The CCAAT/enhancer binding protein (C/EBP) δ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-β peptide.","date":"2011","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/21492414","citation_count":31,"is_preprint":false},{"pmid":"29482641","id":"PMC_29482641","title":"Transcription factors Tp73, Cebpd, Pax6, and Spi1 rather than DNA methylation regulate chronic transcriptomics changes after experimental traumatic brain injury.","date":"2018","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/29482641","citation_count":30,"is_preprint":false},{"pmid":"27918099","id":"PMC_27918099","title":"MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.","date":"2016","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27918099","citation_count":30,"is_preprint":false},{"pmid":"32661323","id":"PMC_32661323","title":"Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32661323","citation_count":30,"is_preprint":false},{"pmid":"27253061","id":"PMC_27253061","title":"CELF RNA binding proteins promote axon regeneration in C. elegans and mammals through alternative splicing of Syntaxins.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27253061","citation_count":30,"is_preprint":false},{"pmid":"34681716","id":"PMC_34681716","title":"CELF Family Proteins in Cancer: Highlights on the RNA-Binding Protein/Noncoding RNA Regulatory Axis.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34681716","citation_count":29,"is_preprint":false},{"pmid":"33953165","id":"PMC_33953165","title":"Fibroblast CEBPD/SDF4 axis in response to chemotherapy-induced angiogenesis through CXCR4.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33953165","citation_count":29,"is_preprint":false},{"pmid":"26270987","id":"PMC_26270987","title":"Multiple Protein Kinases via Activation of Transcription Factors NF-κB, AP-1 and C/EBP-δ Regulate the IL-6/IL-8 Production by HIV-1 Vpr in Astrocytes.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26270987","citation_count":29,"is_preprint":false},{"pmid":"34065488","id":"PMC_34065488","title":"Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34065488","citation_count":28,"is_preprint":false},{"pmid":"22396222","id":"PMC_22396222","title":"Artemisinic acid is a regulator of adipocyte differentiation and C/EBP δ expression.","date":"2012","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22396222","citation_count":28,"is_preprint":false},{"pmid":"17584860","id":"PMC_17584860","title":"Cloning and embryonic expression patterns of the chicken CELF family.","date":"2007","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/17584860","citation_count":27,"is_preprint":false},{"pmid":"8530045","id":"PMC_8530045","title":"Mouse chromosomal location of the CCAAT/enhancer binding proteins C/EBP beta (Cebpb), C/EBP delta (Cebpd), and CRP1 (Cebpe).","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8530045","citation_count":27,"is_preprint":false},{"pmid":"8774705","id":"PMC_8774705","title":"Nuclear factor kappa B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP beta) and nuclear factor interleukin-6 beta (NFIL6-beta or C/EBP delta) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human breast carcinoma cell line.","date":"1996","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8774705","citation_count":27,"is_preprint":false},{"pmid":"20631008","id":"PMC_20631008","title":"CELF proteins regulate CFTR pre-mRNA splicing: essential role of the divergent domain of ETR-3.","date":"2010","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/20631008","citation_count":27,"is_preprint":false},{"pmid":"17903252","id":"PMC_17903252","title":"Reciprocal regulation of p63 by C/EBP delta in human keratinocytes.","date":"2007","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17903252","citation_count":26,"is_preprint":false},{"pmid":"12554732","id":"PMC_12554732","title":"Posttranscriptional and posttranslational regulation of C/EBP delta in G0 growth-arrested mammary epithelial cells.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12554732","citation_count":26,"is_preprint":false},{"pmid":"24810056","id":"PMC_24810056","title":"The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24810056","citation_count":25,"is_preprint":false},{"pmid":"25403273","id":"PMC_25403273","title":"ABLIM1 splicing is abnormal in skeletal muscle of patients with DM1 and regulated by MBNL, CELF and PTBP1.","date":"2014","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/25403273","citation_count":25,"is_preprint":false},{"pmid":"15694370","id":"PMC_15694370","title":"IL-1 beta-dependent regulation of C/EBP delta transcriptional activity.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15694370","citation_count":23,"is_preprint":false},{"pmid":"34571881","id":"PMC_34571881","title":"CEBPD Potentiates the Macrophage Inflammatory Response but CEBPD Knock-Out Macrophages Fail to Identify CEBPD-Dependent Pro-Inflammatory Transcriptional Programs.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34571881","citation_count":22,"is_preprint":false},{"pmid":"33768129","id":"PMC_33768129","title":"A hierarchical and collaborative BRD4/CEBPD partnership governs vascular smooth muscle cell inflammation.","date":"2021","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/33768129","citation_count":22,"is_preprint":false},{"pmid":"32705251","id":"PMC_32705251","title":"Shikonin inhibits CEBPD downregulation in IL‑17‑treated HaCaT cells and in an imiquimod‑induced psoriasis model.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32705251","citation_count":22,"is_preprint":false},{"pmid":"19617893","id":"PMC_19617893","title":"C/EBP beta and C/EBP delta expression is elevated in the early phase of ethanol-induced hepatosteatosis in mice.","date":"2009","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/19617893","citation_count":22,"is_preprint":false},{"pmid":"19757395","id":"PMC_19757395","title":"Differential expression of the Brunol/CELF family genes during Xenopus laevis early development.","date":"2010","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19757395","citation_count":21,"is_preprint":false},{"pmid":"36831248","id":"PMC_36831248","title":"Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36831248","citation_count":21,"is_preprint":false},{"pmid":"14691721","id":"PMC_14691721","title":"Expression pattern of the CCAAT/enhancer-binding proteins C/EBP-alpha, C/EBP-beta and C/EBP-delta in the human placenta.","date":"2003","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14691721","citation_count":21,"is_preprint":false},{"pmid":"34209741","id":"PMC_34209741","title":"Exosomal microRNA let-7-5p from Taenia pisiformis Cysticercus Prompted Macrophage to M2 Polarization through Inhibiting the Expression of C/EBP δ.","date":"2021","source":"Microorganisms","url":"https://pubmed.ncbi.nlm.nih.gov/34209741","citation_count":21,"is_preprint":false},{"pmid":"17331722","id":"PMC_17331722","title":"Expression of MBNL and CELF mRNA transcripts in muscles with myotonic dystrophy.","date":"2007","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/17331722","citation_count":20,"is_preprint":false},{"pmid":"21980073","id":"PMC_21980073","title":"CEBPD suppresses prolactin expression and prolactinoma cell proliferation.","date":"2011","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21980073","citation_count":20,"is_preprint":false},{"pmid":"22453899","id":"PMC_22453899","title":"Repression of nuclear CELF activity can rescue CELF-regulated alternative splicing defects in skeletal muscle models of myotonic dystrophy.","date":"2012","source":"PLoS currents","url":"https://pubmed.ncbi.nlm.nih.gov/22453899","citation_count":20,"is_preprint":false},{"pmid":"18092000","id":"PMC_18092000","title":"The Cebpd (C/EBPdelta) gene is induced by luteinizing hormones in ovarian theca and interstitial cells but is not essential for mouse ovary function.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18092000","citation_count":20,"is_preprint":false},{"pmid":"19351738","id":"PMC_19351738","title":"Induction of CRP3/MLP expression during vein arterialization is dependent on stretch rather than shear stress.","date":"2009","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19351738","citation_count":18,"is_preprint":false},{"pmid":"9761829","id":"PMC_9761829","title":"Crystallization of the catalytic domain of Clostridium cellulolyticum CeLF cellulase in the presence of a newly synthesized cellulase inhibitor.","date":"1998","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/9761829","citation_count":18,"is_preprint":false},{"pmid":"21143913","id":"PMC_21143913","title":"CCAAT/Enhancer Binding Protein-delta (C/EBP-delta) regulates cell growth, migration and differentiation.","date":"2010","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/21143913","citation_count":18,"is_preprint":false},{"pmid":"29644527","id":"PMC_29644527","title":"Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism.","date":"2018","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29644527","citation_count":18,"is_preprint":false},{"pmid":"10683316","id":"PMC_10683316","title":"CYP2B1 is regulated by C/EBP alpha and C/EBP delta inlung epithelial cells.","date":"2000","source":"Molecular cell biology research communications : MCBRC","url":"https://pubmed.ncbi.nlm.nih.gov/10683316","citation_count":18,"is_preprint":false},{"pmid":"32151175","id":"PMC_32151175","title":"MiR-324-5p/PTPRD/CEBPD axis promotes papillary thyroid carcinoma progression via microenvironment alteration.","date":"2020","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32151175","citation_count":17,"is_preprint":false},{"pmid":"19073192","id":"PMC_19073192","title":"CELF-mediated alternative splicing is required for cardiac function during early, but not later, postnatal life.","date":"2008","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19073192","citation_count":17,"is_preprint":false},{"pmid":"10634518","id":"PMC_10634518","title":"Local signals induce CCAAT/enhancer binding protein-delta (C/EBP-delta) and C/EBP-beta mRNA expression in the involuting mouse mammary gland.","date":"1999","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/10634518","citation_count":17,"is_preprint":false},{"pmid":"29642403","id":"PMC_29642403","title":"Cebpd Is Essential for Gamma-Tocotrienol Mediated Protection against Radiation-Induced Hematopoietic and Intestinal Injury.","date":"2018","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29642403","citation_count":16,"is_preprint":false},{"pmid":"12721415","id":"PMC_12721415","title":"CelF of Orpinomyces PC-2 has an intron and encodes a cellulase (CelF) containing a carbohydrate-binding module.","date":"2003","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12721415","citation_count":16,"is_preprint":false},{"pmid":"28881585","id":"PMC_28881585","title":"C/EBP-δ positively regulates MDSC expansion and endothelial VEGFR2 expression in tumor development.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28881585","citation_count":16,"is_preprint":false},{"pmid":"21541285","id":"PMC_21541285","title":"Expression of a dominant negative CELF protein in vivo leads to altered muscle organization, fiber size, and subtype.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21541285","citation_count":15,"is_preprint":false},{"pmid":"38729272","id":"PMC_38729272","title":"The role of CELF family in neurodevelopment and neurodevelopmental disorders.","date":"2024","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38729272","citation_count":14,"is_preprint":false},{"pmid":"35203290","id":"PMC_35203290","title":"Angiogenesis Driven by the CEBPD-hsa-miR-429-VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35203290","citation_count":14,"is_preprint":false},{"pmid":"34954904","id":"PMC_34954904","title":"Biological significance of MYC and CEBPD coamplification in urothelial carcinoma: Multilayered genomic, transcriptional and posttranscriptional positive feedback loops enhance oncogenic glycolysis.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34954904","citation_count":14,"is_preprint":false},{"pmid":"33809617","id":"PMC_33809617","title":"High-Throughput Screening for CEBPD-Modulating Compounds in THP-1-Derived Reporter Macrophages Identifies Anti-Inflammatory HDAC and BET Inhibitors.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33809617","citation_count":13,"is_preprint":false},{"pmid":"20506344","id":"PMC_20506344","title":"Inhibition of LPS-induced C/EBP delta by trichostatin A has a positive effect on LPS-induced cyclooxygenase 2 expression in RAW264.7 cells.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20506344","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49670,"output_tokens":7185,"usd":0.128392},"stage2":{"model":"claude-opus-4-6","input_tokens":10989,"output_tokens":4416,"usd":0.248018},"total_usd":0.37641,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"CEBPD (NF-IL6β) forms a heterodimer with NF-IL6 (C/EBPβ) in vitro, and the heterodimeric complex binds the same DNA sequences as respective homodimers; CEBPD shows synergistic transcriptional activation with NF-IL6 in transient luciferase assays.\",\n      \"method\": \"In vitro heterodimerization assay, EMSA, transient luciferase reporter assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of heterodimerization combined with DNA-binding and transactivation assays\",\n      \"pmids\": [\"1741402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CEBPD is the major IL-1-inducible protein that binds the C/EBP site in the C3 promoter and trans-activates the human complement C3 gene in an IL-1-responsive manner; CEBPD protein accumulates in the nucleus after IL-1 treatment of Hep3B cells.\",\n      \"method\": \"EMSA with supershift antibodies, Western immunoblot, co-transfection reporter assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — supershift EMSA, Western blot, and functional reporter assay in a single study with rigorous controls\",\n      \"pmids\": [\"8385337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CEBPD (C/EBPδ/NF-IL6β) is transcriptionally induced by IL-6 in Hep3B hepatoma cells and constitutively activates transcription from IL-6 responsive elements (IL-6REs) in the promoters of hemopexin, haptoglobin, and CRP, unlike IL-6DBP/NF-IL6 whose activity is regulated post-translationally.\",\n      \"method\": \"Transient transfection reporter assay, Western blot of nuclear extracts\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, distinguishes transcriptional vs post-translational regulation mechanisms\",\n      \"pmids\": [\"7680115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The human CEBPD gene is intronless and maps to the pericentromeric region of chromosome 8 (8q11), with its protein product binding CCAAT homology and viral enhancer core sequences.\",\n      \"method\": \"cDNA/genomic cloning, FISH, somatic cell hybrid mapping\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal localization by FISH with STS confirmation\",\n      \"pmids\": [\"8314590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CEBPD (NF-IL6β) physically interacts with PU.1 through its leucine zipper domain and the carboxyl-terminal 28 amino acids of PU.1 (Ets domain); the two proteins synergistically activate transcription and can simultaneously bind adjacent DNA sites without altering each other's DNA-binding kinetics.\",\n      \"method\": \"Far Western blot, cDNA library screen, EMSA, transient transfection synergy assay, deletion mutagenesis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Far Western library screen plus EMSA plus functional synergy assay with deletion mapping\",\n      \"pmids\": [\"7594592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Growth hormone induces CEBPD at the transcriptional level (increased mRNA superinducible by cycloheximide) in 3T3-F442A preadipocytes, distinct from its translational activation of C/EBPβ; this induction is not observed with insulin.\",\n      \"method\": \"EMSA, Western blot, Northern blot, pharmacological inhibitors of JAK2 and protein kinase C\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods in a single study distinguishing transcriptional from translational mechanisms\",\n      \"pmids\": [\"7760844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"VIP, PACAP, and noradrenaline induce CEBPD expression in cortical astrocytes via the cAMP second-messenger pathway; CEBPD behaves as a cAMP-inducible immediate-early gene, and forced expression of CEBPD enhances glycogen resynthesis in astrocytes.\",\n      \"method\": \"Northern blot, protein synthesis inhibitor assays, transfection with expression vectors measuring glycogen resynthesis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — immediate-early gene evidence plus functional rescue via CEBPD overexpression\",\n      \"pmids\": [\"8558260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CEBPD expression is induced in mammary epithelial cells (COMMA D) arrested in G0 by serum/growth factor withdrawal or contact inhibition; antisense-mediated loss of CEBPD markedly delays growth arrest, establishing a role for CEBPD in G0 arrest.\",\n      \"method\": \"Northern blot, Western blot, EMSA, antisense construct transfection, BrdU incorporation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with antisense plus multiple molecular readouts in a single study\",\n      \"pmids\": [\"9045647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CEBPD and C/EBPα transactivate the CYP2B1 promoter in lung epithelial cells; a proximal C/EBP-binding site in the CYP2B1 promoter is necessary for this transactivation, as shown by site-directed mutagenesis.\",\n      \"method\": \"Transient transfection reporter assay, EMSA, site-directed mutagenesis\",\n      \"journal\": \"Molecular cell biology research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis plus functional reporter assay\",\n      \"pmids\": [\"10683316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CEBPD is essential for the second (de novo protein synthesis-dependent) phase of LPS-induced COX-2 mRNA induction in macrophages; C/EBPβ-knockout macrophages are defective in both phases, and CEBPD synthesis is induced by LPS in a MAPK/SAPK2/p38-dependent manner.\",\n      \"method\": \"C/EBPβ-knockout macrophages, pharmacological inhibition of MAPK and p38 cascades, Northern blot, Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout model combined with pharmacological pathway dissection\",\n      \"pmids\": [\"11668179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CEBPD protein levels are short-lived in G0-arrested mammary epithelial cells (t½ ~120 min); C/EBPδ protein is degraded in a ubiquitin-dependent manner, primarily in the nucleus, during G0 growth arrest.\",\n      \"method\": \"Protein half-life assays with translation inhibitors, ubiquitin-dependent proteasome inhibitor assays, nuclear/cytoplasmic fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological evidence for ubiquitin-dependent nuclear degradation with multiple inhibitors\",\n      \"pmids\": [\"12554732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-1β regulates CEBPD transcriptional activity through p38 MAP kinase; a docking site for p38 MAPK located between amino acids 75–85 is necessary for CEBPD phosphorylation, and a transactivation domain between amino acids 70–108 is required for IL-1-dependent haptoglobin induction and p300-dependent transactivation.\",\n      \"method\": \"p38 kinase inhibitor (SB203580), deletion mutagenesis, transient transfection reporter assay, Northern blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis mapping of kinase docking site and transactivation domain with functional validation\",\n      \"pmids\": [\"15694370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ΔNp63α represses CEBPD expression in keratinocytes; CEBPD in turn binds to and activates the ΔNp63 promoter, establishing a reciprocal regulatory loop; CEBPD is found on p63 target gene promoters in vivo by ChIP analysis.\",\n      \"method\": \"RNAi screening, RT-PCR, ChIP, reporter assay, overexpression and inactivation studies\",\n      \"journal\": \"BMC molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal regulation validated by ChIP and functional reporter assay with siRNA knockdown\",\n      \"pmids\": [\"17903252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CEBPD is sumoylated at lysine 120 by SUMO1; sumoylated CEBPD recruits HDAC1 and HDAC3 to the PPARG2 promoter to inactivate transcription, while non-sumoylated CEBPD acts as an activator; identified two CEBPD-binding motifs on the PPARG2 promoter at −324/−311 and −158/−145.\",\n      \"method\": \"5'-serial deletion reporter analysis, site-directed mutagenesis of CEBPD binding sites, in vivo ChIP, sumoylation mutant constructs\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — SUMO modification identified, functional consequences dissected via mutagenesis and ChIP in a single study\",\n      \"pmids\": [\"18619497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CEBPD induces expression of the CDC27/APC3 subunit of the APC/C complex, leading to polyubiquitination and proteasomal degradation of cyclin D1; CEBPD also down-regulates cyclin B1, Skp2, and Plk-1; in CEBPD knockout MEFs, Cdc27 levels are reduced and cyclin D1 levels are elevated.\",\n      \"method\": \"CEBPD knockout MEF analysis, siRNA silencing, Western blot, co-immunoprecipitation/ubiquitination assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockout and siRNA combined with mechanistic ubiquitination assays across multiple cell types\",\n      \"pmids\": [\"20439707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CEBPD physically interacts with FANCD2 and importin 4 (IPO4) via separate domains, mediating FANCD2-IPO4 association and augmenting nuclear import of FANCD2; this promotes FANCD2 monoubiquitination required for DNA repair; this is a transcription-independent function of CEBPD.\",\n      \"method\": \"Co-immunoprecipitation, gene knockout, protein overexpression/depletion, nuclear import assays, FANCD2 monoubiquitination assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with multiple domains, genetic knockout, and functional monoubiquitination readout\",\n      \"pmids\": [\"20805509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CEBPD induces expression of PTX3 (pentraxin-3) in astrocytes, and PTX3 participates in attenuating macrophage-mediated phagocytosis of damaged neuron cells, establishing an astrocyte CEBPD→PTX3 axis in neuroinflammation.\",\n      \"method\": \"Global gene expression profiling, reporter assays, siRNA knockdown, phagocytosis functional assays\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — gene expression profiling plus functional phagocytosis assay, single lab\",\n      \"pmids\": [\"21112127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CEBPD directly transactivates the SOD1 promoter, reducing cisplatin-induced reactive oxygen species and apoptosis in bladder carcinoma cells, conferring drug resistance.\",\n      \"method\": \"Reporter assay, ChIP, siRNA knockdown, ROS measurement, apoptosis assay\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter transactivation confirmed by ChIP plus functional ROS/apoptosis readout\",\n      \"pmids\": [\"20385105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CEBPD and STAT-1 are required for basal and R848-stimulated transcriptional activity of the human TLR8 promoter; CEBPD binds three C/EBP cis-acting elements in the TLR8 promoter, with enhanced binding upon R848 stimulation.\",\n      \"method\": \"Luciferase reporter assay, ChIP assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay combined with ChIP confirmation of CEBPD binding\",\n      \"pmids\": [\"20829351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CEBPD inhibits prolactin (PRL) expression by binding to the PRL promoter and suppressing PRL promoter activity (96% suppression); CEBPD physically interacts with Pit1 and attenuates each other's binding to the PRL promoter; CEBPD also suppresses c-Myc, survivin, and cyclins B1, B2, and D1 expression.\",\n      \"method\": \"ChIP, luciferase reporter assay, co-immunoprecipitation, siRNA knockdown, microarray gene expression profiling\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP combined with Co-IP and functional reporter assay showing CEBPD-Pit1 interaction at PRL promoter\",\n      \"pmids\": [\"21980073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CEBPD regulates VEGF-C and VEGFR3 expression in lymphatic endothelial cells (LECs) to drive lymphangiogenesis; CEBPD expression is induced by hypoxia, and CEBPD regulates HIF-1α which in turn mediates VEGF-C and VEGFR3 upregulation; genetic deletion of CEBPD in mice reduces lymphangiogenesis and pulmonary metastases.\",\n      \"method\": \"CEBPD knockout mice, forced expression and knockdown in LECs, in vitro migration and network formation assays, Western blot, reporter assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knockout mouse model combined with in vitro gain/loss-of-function and mechanistic pathway dissection\",\n      \"pmids\": [\"21666710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CEBPD has anti-apoptotic and anti-inflammatory roles in pancreatic β-cells; CEBPD deficiency exacerbates cytokine-induced apoptosis through increased CHOP and BIM expression; CEBPD deficiency boosts chemokine production (CXCL1, 9, 10, CCL20) by hampering IRF-1 upregulation and increasing STAT1 activation.\",\n      \"method\": \"siRNA knockdown, double knockdown epistasis, overexpression, caspase cleavage assays, ELISA for chemokines\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — double knockdown epistasis establishing pathway order, combined with gain-of-function rescue experiments\",\n      \"pmids\": [\"22347430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The transcription factor Miz1 terminates LPS-induced inflammation by repressing CEBPD transcription; after LPS stimulation, Miz1 is phosphorylated at Ser178, which is required for recruitment of HDAC1 to repress the CEBPD gene, thereby limiting proinflammatory cytokine expression.\",\n      \"method\": \"Genetic disruption of Miz1 POZ domain in mice, Miz1 Ser178 mutagenesis, HDAC1 co-immunoprecipitation/ChIP, cytokine measurement\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo mouse genetic model combined with phosphorylation site mutagenesis and HDAC1 recruitment assays\",\n      \"pmids\": [\"23525087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CEBPD expression is induced by cisplatin through the EGFR/STAT3 pathway in bladder carcinoma cells; CEBPD then directly activates ABCB1 and ABCC2 drug transporter genes, conferring cross-resistance to paclitaxel; inhibition of EGFR or STAT3 reverses this resistance.\",\n      \"method\": \"siRNA loss-of-function, reporter assay, ChIP, xenograft animal assay, EGFR/STAT3 inhibitors\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-confirmed direct CEBPD binding to ABCB1/ABCC2 promoters, validated in vivo with xenografts\",\n      \"pmids\": [\"27435393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DN-ATF5 associates in cells with CEBPB and CEBPD (and CCDC6) via leucine zipper interactions, blocking formation of transcriptionally active CEBPB and CEBPD homodimers and heterodimers; CEBPB or CEBPD knockdown promotes apoptosis in cancer cells but not normal astrocytes.\",\n      \"method\": \"Unbiased pull-down with mass spectrometry, immunoblotting, siRNA knockdown, transcriptional activity assays\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased MS-based pull-down combined with functional siRNA knockdown across multiple cell lines\",\n      \"pmids\": [\"31676720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IPO4 (importin 4) augments nuclear translocation of CEBPD through nuclear localization signals (NLS); nuclear CEBPD then transcriptionally upregulates PRKDC (DNA-PKcs), activating DNA damage repair; cisplatin treatment strengthens CEBPD transcriptional activity toward PRKDC.\",\n      \"method\": \"shRNA knockdown, reporter assay, nuclear fractionation, in vivo xenograft, loss-of-function assays in cervical cancer cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (IPO4→CEBPD nuclear import→PRKDC transcription) established by multiple functional assays\",\n      \"pmids\": [\"32661323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SUMOylation of PUM2 (by UBE2I/SUMO2/3) decreases the ability of PUM2 to inhibit CEBPD mRNA stability; elevated CEBPD then binds the DSG2 promoter to upregulate DSG2, promoting vasculogenic mimicry in glioma cells.\",\n      \"method\": \"Co-IP, immunofluorescence, RNA immunoprecipitation (RIP), ChIP, luciferase assay, 3D cell culture VM assay\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (RIP, ChIP, Co-IP) establishing the UBE2I/PUM2/CEBPD/DSG2 axis\",\n      \"pmids\": [\"32997416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRD4 controls CEBPD expression via its bromodomain-1 (not bromodomain-2) by binding a H3K27ac-marked enhancer at the Cebpd locus; BRD4 and CEBPD proteins physically co-immunoprecipitate and co-occupy the Cebpd promoter and enhancer DNA, forming a BRD4/CEBPD/promoter/enhancer complex that is disrupted by JQ1.\",\n      \"method\": \"ChIP-seq, genomic enhancer deletion, siRNA silencing, reciprocal Co-IP, BRD4 bromodomain-specific constructs\",\n      \"journal\": \"Molecular therapy. Methods & clinical development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq, reciprocal Co-IP, and enhancer deletion combined with bromodomain-specific dissection in a single study\",\n      \"pmids\": [\"33768129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Deletion of the CEBPD transactivation domain (ΔTAD) reveals that the context-dependent role of CEBPD in macrophage cytokine production depends on compensatory transcriptional activity; CRISPR-generated ΔTAD macrophages reveal a large discrepancy between transcriptional programs in CEBPD knockout vs. CEBPD-ΔTAD macrophages.\",\n      \"method\": \"CRISPR-Cas9 endogenous TAD deletion, RNA-seq comparison of KO vs. ΔTAD macrophages, LPS stimulation assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR-generated separation-of-function allele with transcriptomic comparison, single lab\",\n      \"pmids\": [\"34571881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In glioblastoma, HIF1α and HIF2α activate the CEBPD promoter under hypoxia; CEBPD in turn directly binds and activates the FN1 (fibronectin) promoter; FN1 and its integrin receptors mediate CEBPD-induced EGFR phosphorylation and PI3K pathway activation, promoting invasion.\",\n      \"method\": \"Proteomic analysis, TF binding analysis, HIF1α/HIF2α overexpression, ChIP-qPCR/ChIP-seq, luciferase reporter assay, Western blot\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP-seq and luciferase reporter validating direct CEBPD binding to FN1 promoter, mechanistic pathway established\",\n      \"pmids\": [\"37059730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CEBPD acts as a key transcription factor in IL-21-engineered NK cells; deletion of CEBPD reduces IL-21 NK cell cytotoxicity and metabolic fitness, while overexpression enhances long-term anti-tumor activity, placing CEBPD downstream of IL-21 signaling in NK cell functional reprogramming.\",\n      \"method\": \"CEBPD deletion and overexpression in NK cells, chromatin accessibility (ATAC-seq), in vivo GBM models, cytotoxicity and metabolic assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss- and gain-of-function combined with chromatin accessibility sequencing and in vivo models\",\n      \"pmids\": [\"39137729\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CEBPD is an inducible bZIP transcription factor that forms homodimers and heterodimers (notably with C/EBPβ and Pit1) to directly transactivate or repress target gene promoters (including C3, COX-2, TLR8, PRL, SOD1, ABCB1/C2, FN1, VEGFR2, CDC27/APC3, PRKDC); its activity is modulated post-translationally by p38 MAPK-mediated phosphorylation, SUMO1 modification at K120 (recruiting HDAC1/3 for repression), and ubiquitin-dependent nuclear proteasomal degradation; it also performs transcription-independent functions by scaffolding FANCD2–importin 4 complexes to promote nuclear import and monoubiquitination of FANCD2 in DNA damage repair; CEBPD expression is controlled upstream by IL-1/IL-6/LPS signaling, cAMP pathway activation, EGFR/STAT3 signaling, BRD4 enhancer activity, and negative regulation by Miz1-HDAC1-mediated transcriptional repression.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CEBPD is an inducible bZIP transcription factor that functions as a central integrator of inflammatory, growth-arrest, and stress-responsive gene programs by forming homodimers and heterodimers with C/EBPβ, PU.1, and Pit1 to activate or repress diverse target promoters including C3, COX-2, TLR8, PRL, SOD1, ABCB1/ABCC2, FN1, CDC27/APC3, and PRKDC [PMID:1741402, PMID:8385337, PMID:20439707, PMID:27435393, PMID:37059730]. Its transcriptional activity is tightly modulated by p38 MAPK-mediated phosphorylation at a docking site between residues 75–85, SUMO1 modification at K120 that switches CEBPD from an activator to a repressor by recruiting HDAC1/3, and ubiquitin-dependent nuclear proteasomal degradation [PMID:15694370, PMID:18619497, PMID:12554732]. Beyond transcription, CEBPD performs a scaffolding function by bridging FANCD2 and importin 4 to promote FANCD2 nuclear import and monoubiquitination required for DNA damage repair [PMID:20805509]. CEBPD expression is controlled upstream by IL-1/IL-6/LPS, cAMP, EGFR/STAT3, hypoxia/HIF, and BRD4-dependent enhancer activity, and is terminated by Miz1-HDAC1-mediated transcriptional repression [PMID:8385337, PMID:7680115, PMID:23525087, PMID:33768129, PMID:37059730].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Establishing that CEBPD heterodimerizes with C/EBPβ and that the heterodimer binds the same DNA elements as homodimers resolved the fundamental question of how the C/EBP family achieves combinatorial transcriptional control.\",\n      \"evidence\": \"In vitro heterodimerization, EMSA, and luciferase reporter assays\",\n      \"pmids\": [\"1741402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and relative affinity of heterodimer vs. homodimer at endogenous promoters unknown\", \"In vivo relevance of heterodimerization not demonstrated\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrating that CEBPD is the principal IL-1- and IL-6-inducible C/EBP family member that transactivates acute-phase gene promoters (C3, hemopexin, haptoglobin, CRP) established CEBPD as the effector linking cytokine signaling to the hepatic acute-phase response.\",\n      \"evidence\": \"Supershift EMSA, Western blot of nuclear accumulation, and reporter assays in Hep3B hepatoma cells after IL-1 or IL-6 treatment\",\n      \"pmids\": [\"8385337\", \"7680115\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of CEBPD relative to C/EBPβ at endogenous acute-phase loci not quantified\", \"In vivo acute-phase response in CEBPD-null animals not yet tested at this stage\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identifying that CEBPD synergizes with PU.1 via direct leucine-zipper-to-Ets-domain contact, and that growth hormone transcriptionally induces CEBPD independently of insulin, broadened the upstream signals and cooperative partners controlling CEBPD activity.\",\n      \"evidence\": \"Far Western, deletion mutagenesis, EMSA, and synergy reporter assay for PU.1; Northern blot with cycloheximide superinduction for GH induction\",\n      \"pmids\": [\"7594592\", \"7760844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genomic targets co-regulated by CEBPD–PU.1 not identified\", \"Signaling intermediates between GH receptor and CEBPD promoter not mapped\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showing that CEBPD behaves as a cAMP-inducible immediate-early gene in astrocytes and that its forced expression enhances glycogen resynthesis established a metabolic effector role outside the immune system.\",\n      \"evidence\": \"Northern blot with protein synthesis inhibitors and CEBPD overexpression glycogen resynthesis assay in cortical astrocytes\",\n      \"pmids\": [\"8558260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes mediating glycogen resynthesis not identified\", \"In vivo brain metabolic phenotype of CEBPD loss not tested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrating that CEBPD is induced during G0 arrest and that antisense-mediated loss delays growth arrest provided the first functional evidence that CEBPD is required for cell cycle exit.\",\n      \"evidence\": \"Antisense knockdown, BrdU incorporation, Northern/Western blot in mammary epithelial cells\",\n      \"pmids\": [\"9045647\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating G0 arrest unknown at this point\", \"Mechanism distinguishing CEBPD from C/EBPα in growth arrest not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Revealing that CEBPD protein has a short half-life (~120 min) and is degraded by ubiquitin-dependent nuclear proteasomal pathways during G0 explained how CEBPD protein levels are dynamically controlled despite ongoing transcription.\",\n      \"evidence\": \"Translation inhibitor chase, proteasome inhibitors, nuclear/cytoplasmic fractionation in mammary epithelial cells\",\n      \"pmids\": [\"12554732\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ubiquitin ligase responsible for CEBPD degradation not identified\", \"Ubiquitination sites on CEBPD not mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapping a p38 MAPK docking site (aa 75–85) and a transactivation domain (aa 70–108) on CEBPD that are required for IL-1-dependent gene activation resolved how inflammatory signaling post-translationally enhances CEBPD transcriptional potency.\",\n      \"evidence\": \"Deletion mutagenesis, p38 inhibitor SB203580, reporter assays, Northern blot in hepatoma cells\",\n      \"pmids\": [\"15694370\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phosphorylation sites on CEBPD targeted by p38 not identified by mass spectrometry\", \"Whether p38 phosphorylation alters CEBPD protein stability not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovering that SUMO1 modification at K120 converts CEBPD from a transcriptional activator to a repressor by recruiting HDAC1/3 (demonstrated at the PPARγ2 promoter) established a post-translational switch mechanism governing CEBPD's dual activator/repressor functions.\",\n      \"evidence\": \"SUMOylation mutant constructs, ChIP for HDAC1/3 recruitment, serial deletion and site-directed mutagenesis of PPARγ2 promoter\",\n      \"pmids\": [\"18619497\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals that control the balance between sumoylated and non-sumoylated CEBPD unknown\", \"Genome-wide identification of SUMO-dependent CEBPD repression targets not performed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"A burst of studies in 2010 established multiple new CEBPD functions: transcriptional activation of CDC27/APC3 leading to cyclin D1 degradation (linking CEBPD to cell cycle control via the APC/C), direct transactivation of SOD1 conferring cisplatin resistance, regulation of TLR8 transcription, induction of PTX3 in neuroinflammation, and — critically — a transcription-independent scaffolding role bridging FANCD2 and importin 4 for DNA damage repair.\",\n      \"evidence\": \"CEBPD knockout MEFs, siRNA, ubiquitination assays for CDC27/cyclin D1; ChIP and ROS assays for SOD1; ChIP for TLR8; reciprocal Co-IP, nuclear import assays, and FANCD2 monoubiquitination readouts for the scaffolding function\",\n      \"pmids\": [\"20439707\", \"20385105\", \"20829351\", \"20805509\", \"21112127\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the CEBPD–FANCD2–IPO4 ternary complex not determined\", \"Relative importance of transcription-dependent vs. -independent CEBPD functions in DNA damage response unclear\", \"Whether CEBPD scaffolding role extends to other Fanconi pathway substrates unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identifying CEBPD as a repressor of prolactin expression through physical interaction with Pit1, and as a regulator of VEGF-C/VEGFR3-driven lymphangiogenesis via HIF-1α, expanded CEBPD's roles to endocrine regulation and tumor-associated vascular remodeling.\",\n      \"evidence\": \"ChIP, Co-IP of CEBPD–Pit1, reporter assays for PRL; CEBPD knockout mice showing reduced lymphangiogenesis and metastasis\",\n      \"pmids\": [\"21980073\", \"21666710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CEBPD–Pit1 interaction interface not structurally resolved\", \"Whether CEBPD-dependent lymphangiogenesis operates independently of its cell-cycle arrest functions unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that Miz1 terminates LPS-induced inflammation by recruiting HDAC1 to repress CEBPD transcription (dependent on Miz1 Ser178 phosphorylation) identified a key negative feedback mechanism that limits CEBPD-driven inflammatory gene expression.\",\n      \"evidence\": \"Miz1 POZ domain disruption in mice, Ser178 mutagenesis, HDAC1 ChIP at CEBPD promoter, cytokine measurements\",\n      \"pmids\": [\"23525087\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for Miz1 Ser178 phosphorylation not identified\", \"Whether other C/EBP family members are similarly repressed by Miz1 not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing that cisplatin induces CEBPD through the EGFR/STAT3 axis and that CEBPD directly activates ABCB1 and ABCC2 drug transporter genes established CEBPD as a mediator of chemotherapy cross-resistance, validated in xenograft models.\",\n      \"evidence\": \"ChIP at ABCB1/ABCC2 promoters, siRNA, EGFR/STAT3 inhibitors, xenograft assays in bladder carcinoma\",\n      \"pmids\": [\"27435393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CEBPD-mediated drug resistance operates in tumor types beyond bladder carcinoma not tested\", \"Contribution of CEBPD vs. other transcription factors to ABCB1 induction not quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovering that BRD4 controls CEBPD expression through bromodomain-1-dependent binding to an H3K27ac-marked enhancer, and that BRD4 and CEBPD physically interact and co-occupy the Cebpd locus, revealed an epigenetic feedforward loop governing CEBPD transcription that is pharmacologically targetable by JQ1.\",\n      \"evidence\": \"ChIP-seq, enhancer deletion, reciprocal Co-IP, bromodomain-specific constructs, JQ1 disruption\",\n      \"pmids\": [\"33768129\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the BRD4–CEBPD loop operates genome-wide at other CEBPD target genes not established\", \"Contribution of BRD4 BD1 vs. BD2 at other C/EBP family gene loci unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that HIF1α/HIF2α activate the CEBPD promoter under hypoxia and that CEBPD directly binds and activates the FN1 promoter to drive EGFR/PI3K-mediated glioblastoma invasion established a hypoxia→CEBPD→FN1→integrin signaling axis in tumor progression.\",\n      \"evidence\": \"ChIP-seq, ChIP-qPCR, luciferase reporter, HIF overexpression, proteomic and Western blot analyses in glioblastoma cells\",\n      \"pmids\": [\"37059730\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the HIF–CEBPD–FN1 axis operates in non-CNS hypoxic tumors not tested\", \"Relative contribution of HIF1α vs. HIF2α to CEBPD induction not quantified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying CEBPD as a key downstream effector of IL-21 signaling in NK cells — where its deletion reduces cytotoxicity and metabolic fitness and its overexpression enhances long-term anti-tumor activity — placed CEBPD as a functional reprogramming factor in innate immune effector cells.\",\n      \"evidence\": \"CEBPD deletion and overexpression in NK cells, ATAC-seq, in vivo GBM models, cytotoxicity and metabolic assays\",\n      \"pmids\": [\"39137729\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets of CEBPD in NK cells not catalogued\", \"Whether CEBPD operates similarly in other innate lymphoid cell subsets not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Despite extensive characterization of CEBPD's transcriptional targets and post-translational regulation, several core mechanistic questions remain: the E3 ligase(s) mediating CEBPD ubiquitin-dependent degradation, the structural basis of the CEBPD–FANCD2–IPO4 scaffolding complex, the genome-wide map of SUMO-dependent CEBPD repression targets, and the signals controlling the activator-to-repressor switch via SUMOylation are unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"E3 ubiquitin ligase for CEBPD not identified\", \"No structural model of CEBPD in any complex\", \"Genome-wide SUMO-dependent repression targets not mapped\", \"Integration of transcription-dependent and -independent CEBPD functions in DNA damage not modeled\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 2, 13, 18, 19, 29]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 8, 13, 14, 17, 19, 23, 29, 30]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 10, 15, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0074160\", \"supporting_discovery_ids\": [0, 1, 2, 8, 13, 14, 17, 19, 23, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 18, 22, 30]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [15, 25]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [7, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [21, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 20, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CEBPB\", \"PU.1\", \"FANCD2\", \"IPO4\", \"HDAC1\", \"BRD4\", \"Pit1\", \"ATF5\"],\n    \"other_free_text\": []\n  }\n}\n```"}